Dec. 17 (Bloomberg) -- Gilead Sciences Inc., the California-based maker of the HIV treatment Truvada, asked the U.S. Food and Drug Administration to approve the medicine for use in preventing the disease, the Financial Times reported.
If the request is approved, Truvada could significantly boost Gilead’s sales and help prevent the spread of a disease that infects nearly 2.7 million people a year and kills 1.8 million, the newspaper reported today. The drug is currently the “backbone” of HIV treatment worldwide, the FT said.
The preventative use of Truvada could also cause problems for Gilead, such as undermining the effectiveness of the drug for current patients and triggering lawsuits by uninfected people who experience side effects or become infected, according to the article.
To contact the reporter on this story: Erik Larson in London at firstname.lastname@example.org
To contact the editor responsible for this story: Anthony Aarons at email@example.com